Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Company Overview

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH. Resmetirom has been engineered to target liver tissue in order to reduce hepatic fat accumulation, improve lipid profiles and attenuate fibrosis. The company’s clinical programs include global trials across North America, Europe and Latin America, reflecting its commitment to registering resmetirom in major markets.

In addition to its lead asset, Madrigal is advancing next-generation compounds for lipid disorders and other cardiovascular risk factors. The company engages in strategic collaborations to bolster its research capabilities and expand its therapeutic portfolio. Through a combination of in-house development and partnerships, Madrigal aims to bring multiple first-in-class or best-in-class therapies to patients.

Founded in 2013 and headquartered in Conshohocken, Pennsylvania, Madrigal is led by President and Chief Executive Officer Paul A. Friedman, M.D. The company’s management team comprises experienced biopharmaceutical executives and clinical researchers dedicated to transforming the treatment landscape for metabolic and liver diseases.

Key Stats

• Today's Range: $512.28 to $542.00
• 50-Day Range: $425.85 to $546.89
• 52-Week Range: $265.00 to $615.00
• Volume: 384,297 shs
• Average Volume: 350,975 shs
• Market Capitalization: $12.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $682.07
• Consensus Rating: Moderate Buy

Madrigal Pharmaceuticals Stock Analysis - MarketRank™

Madrigal Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 325th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 1 strong buy rating, 12 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Madrigal Pharmaceuticals has a consensus price target of $682.07, representing about 27.5% upside from its current price of $534.86.

Amount of Analyst Coverage

Madrigal Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($5.49) to $12.45 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Madrigal Pharmaceuticals is -41.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Madrigal Pharmaceuticals is -41.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Madrigal Pharmaceuticals has a P/B Ratio of 20.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.28% of the float of Madrigal Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 12.69, which indicates bearish sentiment.

Change versus previous month

Short interest in Madrigal Pharmaceuticals has recently increased by 2.65%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Madrigal Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Madrigal Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.43

News Sentiment

Madrigal Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Madrigal Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

MarketBeat Follows

6 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,626,254.00 in company stock.

Percentage Held by Insiders

21.50% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MDGL Stock Analysis - Frequently Asked Questions

How have MDGL shares performed this year?

Madrigal Pharmaceuticals' stock was trading at $582.34 at the beginning of the year. Since then, MDGL shares have decreased by 8.2% and is now trading at $534.86.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($3.25) earnings per share for the quarter, beating the consensus estimate of ($3.61) by $0.36. The company's revenue was up 126.8% compared to the same quarter last year.
Read the conference call transcript.

Who are Madrigal Pharmaceuticals' major shareholders?

Top institutional investors of Madrigal Pharmaceuticals include Pictet Asset Management Holding SA (0.82%), Bank of New York Mellon Corp (0.59%), Candriam S.C.A. (0.37%) and Emerald Advisers LLC (0.16%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Paul A Friedman, William John Sibold, Richard S Levy, Brian Joseph Lynch, Carole Huntsman, Mardi Dier, Shannon T Kelley, Fred B Craves, Robert E Waltermire, Kenneth Bate and James M Daly.
View institutional ownership trends.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY).

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MDGL
• CIK: 1157601
• Web: www.madrigalpharma.com
• Phone: (267) 824-2827
• Fax: 781-274-8228
• Employees: 90
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Madrigal Pharmaceuticals: $682.07
• High Price Target: $964.00
• Low Price Target: $529.00
• Potential Upside/Downside: +27.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.76
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$288.28 million
• Net Margins: -30.08%
• Pretax Margin: -30.08%
• Return on Equity: -43.76%
• Return on Assets: -24.88%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 4.01
• Quick Ratio: 3.77

Sales & Book Value

• Annual Sales: $958.40 million
• Price / Sales: 12.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $26.54 per share
• Price / Book: 20.15

Miscellaneous

• Outstanding Shares: 23,040,000
• Free Float: 18,088,000
• Market Cap: $12.32 billion
• Optionable: Optionable
• Beta: -1.04